DiaMedica Therapeutics (DMAC)
(Real Time Quote from BATS)
$4.50 USD
+0.14 (3.21%)
Updated Aug 5, 2025 02:10 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DMAC 4.50 +0.14(3.21%)
Will DMAC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DMAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DMAC
ALGN Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
Best Momentum Stocks to Buy for October 14th
DMAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for October 14th
Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
Other News for DMAC
DiaMedica Therapeutics (DMAC) Plans to Offer 8.61 Million Common Shares
DiaMedica Therapeutics files to sell 8.61M common shares for holders
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement | DMAC Stock News
DiaMedica (DMAC) Secures $30.1M in Private Placement to Advance Drug Development | DMAC Stock News
DiaMedica Therapeutics to sell 8.606M shares at $3.50 in private placement